TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC.
Feng H, Xu H, Shi X, Ding G, Yan C, Li L, Jian Z, Yang X, Guo H, Li F, Zhang J, Ren X.
Feng H, et al. Among authors: li f, li l.
Front Biosci (Landmark Ed). 2023 Jul 24;28(7):147. doi: 10.31083/j.fbl2807147.
Front Biosci (Landmark Ed). 2023.
PMID: 37525904
Free article.